Skip to content

Long-Term Debt at other companies

Eli Lilly logo
Eli LillyLLY
$39.37B+14.1%
Arcutis Biotherapeutics, Inc. logo
Arcutis Biotherapeutics, Inc.ARQT
$101.47M-5.7%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$404.3M+36.5%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$37.53B-2.2%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$1.99B+0.1%

Other financials

Income statement

See full
Operating income-$70.0M-47.5%
Net income-$69.7M-74.5%
EPS (diluted)-$0.98-55.6%

Balance sheet

See full
Cash & equivalents$298.5M+9.9%
Total debt$100.8M+33.3%
Total equity$254.0M-37.7%
Total assets$400.4M-21.7%

Cash flow

See full
Operating cash flow-$66.3M-73.8%
CapEx--100%
Free cash flow-$66.3M-73.6%

Valuation

See full
Market cap$1.56B-45.9%
Enterprise value$1.36B-50.0%

Returns & leverage

See full
Return on equity-77.7%-221pp
Debt / equity0.4×+0.2×
Current ratio8.6×-12.5×

Where this comes from

Reported directly by MoonLake Immunotherapeutics in its filing.

Tagged under the XBRL concept us-gaap:LongTermDebt.

The official record: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about MoonLake Immunotherapeutics's long-term debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MoonLake Immunotherapeutics's long-term debt?
MoonLake Immunotherapeutics (MLTX) reported long-term debt of $99.02M in Q1 2026.
How has MoonLake Immunotherapeutics's long-term debt changed year-over-year?
MoonLake Immunotherapeutics's long-term debt increased by 35.6% year-over-year, from $73.02M to $99.02M.
What does long-term debt mean?
Bonds, term loans, notes payable, and other borrowings with maturities beyond one year — the primary long-term financing source.